Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Belay Tizazu"'
Autor:
Belay Tizazu Mengistie
Publikováno v:
Journal of Socioeconomics and Development. 5:175
Court fees in Ethiopia are governed by the Court Fees Regulation Number 177/1945. Although many things have changed over the past 67 years, none of the consecutive governments attempted to revise the court fee system. The user charge on judicial liti
Autor:
Mengistie, Belay Tizazu
Publikováno v:
Journal of Socioeconomics & Development; Oct2022, Vol. 5 Issue 2, p175-187, 13p
Autor:
Wen-Hsin Liu, Sophie M. Stief, Philipp A. Greif, Klaus H. Metzeler, Irmela Jeremias, Michael D. Bartoschek, Gunnar Schotta, Michela Carlet, Hilmar Quentmeier, Anna-Li Hanneforth, Heinrich Leonhardt, Maja Rothenberg-Thurley, Wolfgang Hiddemann, Sabrina Weser, Sebastian Vosberg, Karsten Spiekermann, Julia M. Kempf, Sebastian Bultmann, Helena Domínguez Moreno, Binje Vick, Raphael Mattes, Bianka Ksienzyk, Matthias Oettle, Belay Tizazu
Publikováno v:
Leukemia
Leukemia 34, 50-62 (2020)
Leukemia 34, 50-62 (2020)
Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm resulting from the malignant transformation of myeloid progenitors. Despite intensive chemotherapy leading to initial treatment responses, relapse caused by intrinsic or acquired drug
Autor:
Evelyn Zellmeier, Nikola P. Konstandin, Maja Rothenberg, Nadine Sandhöfer, Annika Dufour, Klaus H. Metzeler, Belay Tizazu, Karsten Spiekermann, Katrin Reiter, Wolfgang Hiddemann, Julia Bauer, Harald Polzer, Philipp A. Greif
Publikováno v:
Scientific Reports
In acute myeloid leukemia (AML), the Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes. Recently, a new and recurrent juxtamembrane deletion mutation (p.Q569Vfs*2) resulting in a truncated receptor was identified. The muta
Autor:
Gudrun Mellert, Stefan K. Bohlander, Purvi M. Kakadia, Karsten Spiekermann, Hilmar Quentmeier, Jochen Harbott, S Röttgers, Belay Tizazu
Publikováno v:
Leukemia 25, 1645-1649 (2011)
A novel ABL1 fusion to the SH2 containing inositol phosphatase-1 ( SHIP1 ) in acute lymphoblastic leukemia (ALL)
Autor:
Sayantanee Dutta, Georg Leubolt, Wolfgang Hiddemann, Rouzanna Istvanffy, Theresa Sippenauer, Belay Tizazu, Philipp A. Greif, Robert A.J. Oostendorp, Monica Cusan
Publikováno v:
Blood. 132:2779-2779
GATA2 Zinc-Finger (ZF) mutations are associated with specific subgroups of myeloid malignancies. Alterations of the N-terminal ZF1 were identified in AML patients with biallelic CEBPA mutations, whereas the C-terminal ZF2 is typically affected by ger
Publikováno v:
Oncogene. 27:2886-2896
The t(10;11)(p13;q14) translocation leads to the fusion of the CALM and AF10 genes. This translocation can be found as the sole cytogenetic abnormality in acute lymphoblastic leukemia, acute myeloid leukemia and in malignant lymphomas. The expression
Autor:
Maik Dahlhoff, Stefan Krebs, Helmut Blum, Eckhard Wolf, Maja Rothenberg-Thurley, K. Spiekermann, Belay Tizazu, U Zimber-Strobl, Sebastian Vosberg, Stefan K. Bohlander, Sayantanee Dutta, A T Vetter, Alexander Graf, Tobias Herold, Klaus H. Metzeler, Martin Chopra, Marlon R. Schneider, Bianka Ksienzyk, Alexandre Krause, Leticia Quintanilla-Martinez, Philipp A. Greif
Publikováno v:
Leukemia. 30(5)
The CALM/AF10 fusion gene is found in various hematological malignancies including acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia and malignant lymphoma. We have previously identified the leukemia stem cell (LSC) in a CALM/AF10-dri
Autor:
Friederike Schneider, Jan Braess, Andreas Hauser, Helmut Blum, Martin Stanulla, Tobias Herold, Jutta Sturm, Eva Hoster, Wolfgang Hiddemann, Purvi M. Kakadia, Nikola P. Konstandin, Wolfgang E. Berdel, Belay Tizazu, Tobias Benthaus, Thomas Büchner, Evelyn Zellmeier, Stefan K. Bohlander, Karl-Peter Hopfner, Maria Cristina Sauerland, Stefan Krebs, Petra Dörge, Bianka Ksienzyk, Annika Dufour, Alexander Graf, Stephanie Schneider, Bernhard J. Woermann, Karsten Spiekermann, Philipp A. Greif, Marjan Yaghmaie
Publikováno v:
Blood 120, 395-403 (2012)
Cytogenetically normal acute myeloid leukemia (CN-AML) with biallelic CEBPA gene mutations (biCEPBA) represents a distinct disease entity with a favorable clinical outcome. So far, it is not known whether other genetic alterations cooperate with biCE